Compositions and methods for treating estrogen-related medical disorders
US-2015291552-A1 · Oct 15, 2015 · US
US10160752B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10160752-B2 |
| Application number | US-201615382338-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 16, 2016 |
| Priority date | Oct 24, 2012 |
| Publication date | Dec 25, 2018 |
| Grant date | Dec 25, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Disclosed is a compound of formula (I). or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions including the compound of formula (I) and methods of using the compound of formula (I).
Opening claim text (preview).
What is claimed is: 1. A compound having a formula of (II-i): or a pharmaceutically acceptable salt thereof, wherein A 1 is selected from the group consisting of halogen, trifluoromethyl, and —OR 1 ; A 2 is selected from the group consisting of halogen and trifluoromethyl; A 3 is selected from the group consisting of alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocycle, and heteroaryl; A 4 is selected from the group consisting of hydrogen, halogen, cyano, trifluoromethyl, aryl-heteroaryl wherein the aryl is substituted or unsubstituted, and —OR 3 ; R 1 is selected from the group consisting of —SO 3 R x1 and —PO 3 R y1 R z1 ; R 3 is selected from the group consisting of hydrogen, alkyl, —SO 3 R x1 , —PO 3 R y1 R z1 , and —C(═O)R a ; R x1 , R y1 and R z1 , at each occurrence, are independently selected from the group consisting of hydrogen and a pharmaceutically acceptable cation; and R a is alkyl or —OH. 2. A compound selected from the group consisting of: (2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3-yl)(4-(trifluoromethyl)phenyl)methanone; (3-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-2-yl)(4-(trifluoromethyl)phenyl)methanone; cyclopropyl(2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3-yl)methanone; cyclopropyl(3-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-2-yl)methanone; (2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3-yl)(pyridin-4-yl)methanone; (3-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-2-yl)(pyridin-4-yl)methanone; 1-(2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3-yl)-2-methylpropan-1-one; 1-(3-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-2-yl)-2-methylpropan-1-one; (4-ethynylphenyl)(2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3-yl)methanone; (4-ethynylphenyl)(3-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-2-yl)methanone; (3-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-2-yl)(p-tolyl)methanone; (4-(1-(4-fluorophenyl)-1H-1,2,3-triazol-4-yl)phenyl)(2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3-yl)methanone; (4-(1-(4-fluorophenyl)-1H-1,2,3-triazol-4-yl)phenyl)(3-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-2-yl)methanone; (3r,5r,7r)-adamantan-1-yl(2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3-yl)methanone; and (3r,5r,7r)-adamantan-1-yl(3-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-2-yl)methanone; or a pharmaceutically acceptable salt thereof. 3. A compound having a formula of (II-ii): or a pharmaceutically acceptable salt thereof, wherein A 1 is selected from the group consisting of halogen, trifluoromethyl, and —OR 1 ; A 2 is selected from the group consisting of halogen and trifluoromethyl; A 3 is selected from the group consisting of alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocycle, and heteroaryl; A 4 is selected from the group consisting of hydrogen, halogen, alkyl, cyano, trifluoromethyl, aryl-heteroaryl wherein the aryl is substituted or unsubstituted, and —OR 3 ; R 1 , R 2 and R 3 are each independently selected from the group consisting of hydrogen, alkyl, —SO 3 R x1 , —PO 3 R y1 R z1 , and —C(═O)R a ; R x1 , R y1 and R z1 , at each occurrence, are independently selected from the group consisting of hydrogen and a pharmaceutically acceptable cation; and R a is alkyl or —OH.
Drugs for disorders of the cardiovascular system · CPC title
Antineoplastic agents · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Drugs for disorders of the nervous system · CPC title
involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.